Elanco Animal Health (ELAN) EBIT (2017 - 2026)

Elanco Animal Health (ELAN) has 10 years of EBIT data on file, last reported at $291.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 21.25% year-over-year to $291.0 million; the trailing twelve-month figure through Mar 2026 stood at $609.0 million (up 178.89% YoY), and the FY2025 full-year result was $558.0 million, up 136.83% from the prior year.
• EBIT improved to $291.0 million in Q1 2026, from -$44.0 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $291.0 million in Q1 2026 to a low of -$1.6 billion in Q3 2023.
• A 5-year average of -$339.8 million and a median of -$498.0 million in 2022 frame the typical range for EBIT.
• Across the five-year window, EBIT plunged 206.98% in 2023 and surged 147.71% in 2025, its largest moves.
• Tracing ELAN's EBIT over 5 years: stood at -$537.0 million in 2022, then decreased by 19.74% to -$643.0 million in 2023, then grew by 14.15% to -$552.0 million in 2024, then soared by 92.03% to -$44.0 million in 2025, then surged by 761.36% to $291.0 million in 2026.
• Business Quant data shows ELAN's EBIT at $291.0 million in Q1 2026, -$44.0 million in Q4 2025, and $142.0 million in Q3 2025.